On the other hand, cetuximab did not induce CD16a downregulation in blood monocytes and tumor-infiltrating macrophages downregulated CD16a in mice that were treated with F9H4 + cetuximab (Fig. 4G, H). Here, FCGR3A is linked to neoplasm.